Minoxidil Bailleul 5% Solution for cutaneous application

Minoxidil Bailleul 5% Solution for cutaneous application can help improve moderate hair loss (androgenetic alopecia). The active ingredient, Minoxidil, is clinically proven to prevent further hair loss and promote hair regrowth¹.

Features

FDA approved treatment in Androgenetic Alopecia²
Its special formulation allows lighter and less greasy texture
Effective in improving hair density^3,4
Suitable for men
Made in France

Composition: Minoxidil 5%

Indication: For the treatment of certain types of alopecia (excessive hair loss), called androgenetic alopecia, of moderate intensity, in men. It is not recommended in women, due to the high frequency of hypertrichosis (abnormal hair growth) in areas remote from the sites of application.

Dosage: Apply a 1 mL dose (6 sprays) on the scalp twice a day, beginning from the centre of the area to be treated.

Pack Size: 60 mL bottle with a dispensing pump. Box of 1 or 3 bottles.

Precaution: For details, please refer to the package insert.

Storage: Keep out of the reach and sight of children.

Disclaimer & Reference

The content on this site is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or pharmacist with any questions you may have regarding a medical condition.

Reference

Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-553. doi:10.1016/j.jaad.2003.06.014
Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759-3781. doi:10.1111/jocd.14537
Olsen EA, Weiner MS, Amara IA, DeLong ER. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1990;22(4):643-646. doi:10.1016/0190-9622(90)70089-z
Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-774. doi:10.1016/j.jaad.2007.04.012